将 Durvalumab/Bevacizumab 加入 TACE 治疗无法切除的 HCC

{"title":"将 Durvalumab/Bevacizumab 加入 TACE 治疗无法切除的 HCC","authors":"Catlin Nalley","doi":"10.1097/01.cot.0001011492.68618.44","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":510505,"journal":{"name":"Oncology Times","volume":"31 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adding Durvalumab/Bevacizumab to TACE for Unresectable HCC\",\"authors\":\"Catlin Nalley\",\"doi\":\"10.1097/01.cot.0001011492.68618.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":510505,\"journal\":{\"name\":\"Oncology Times\",\"volume\":\"31 10\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Times\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/01.cot.0001011492.68618.44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Times","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.cot.0001011492.68618.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}